A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer

Bibliography

• Tchekmedyian NS. Anemia in cancer patients: significance, epidemiology, and current therapy. Oncology (Williston Park) 2002;16(9 Suppl 10):17-24
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7
   PubMed Web of Science ®Google Scholar
• Achcar RdeO, Cagle PT, Jagirdar J. Expression of activated and latent signal transducer and activator of transcription 3 in 303 non-small cell lung carcinomas and 44 malignant mesotheliomas: possible role for chemotherapeutic intervention. Arch Pathol Lab Med 2007;131:1350-60
   PubMed Web of Science ®Google Scholar
• Bluthe RM, Michaud B, Poli V, Dantzer R. Role of IL-6 in cytokine-induced sickness behavior: a study with IL-6 deficient mice. Physiol Behav 2000;70:367-73
   PubMed Web of Science ®Google Scholar
• Castell JV, Gomez-Lechon MJ, David M, Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989;242:237-9
   PubMed Web of Science ®Google Scholar
• Chang KT, Tsai CM, Chiou YC, IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol 2005;289:L446-53
   PubMed Web of Science ®Google Scholar
• Schafer ZT, Brugge JS. IL-6 involvement in epithelial cancers. J Clin Invest 2007;117:3660-3
   PubMed Web of Science ®Google Scholar
• Staal-van den Brekel AJ, Dentener MA, Schols AM, Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 1995;13:2600-5
   PubMed Web of Science ®Google Scholar
• Nikiteas NI, Tzanakis N, Gazouli M, Serum IL-6, TNFalpha and CRP levels in greek colorectal cancer patients: prognostic implications. World J Gastroenterol 2005;11:1639-43
   PubMed Web of Science ®Google Scholar
• Blay JY, Negrier S, Combaret V, Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992;52:3317-22
   PubMed Web of Science ®Google Scholar
• Pelliniemi TT, Irjala K, Mattila K, Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. finnish leukemia group. Blood 1995;85:765-71
   PubMed Web of Science ®Google Scholar
• Songur N, Kuru B, Kalkan F, Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori 2004;90:196-200
   PubMed Web of Science ®Google Scholar
• Forrest LM, McMillan DC, McArdle CS, Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003;89:1028-30
   PubMed Web of Science ®Google Scholar
• Ganz T, Nemeth E. Iron sequestration and anemia of inflammation. Semin Hematol 2009;46:387-93
   PubMed Web of Science ®Google Scholar
• Ganz T. Hepcidin – a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 2005;18:171-82
   PubMed Web of Science ®Google Scholar
• Buck I, Morceau F, Grigorakaki C, Linking anemia to inflammation and cancer: the crucial role of TNFalpha. Biochem Pharmacol 2009;77:1572-9
   PubMed Web of Science ®Google Scholar
• Adamson JW. The anemia of inflammation/malignancy: mechanisms and management. Hematology Am Soc Hematol Educ Program 2008;24:159-65
   Google Scholar
• Maes K, Nemeth E, Roodman GD, In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood 2010;116:3635-44
   PubMed Web of Science ®Google Scholar
• Tanno T, Rabel A, Alleyne M, Hepcidin, anaemia, and prostate cancer. BJU Int 2011;107:678-9
   PubMed Web of Science ®Google Scholar
• Hohaus S, Massini G, Giachelia M, Anemia in hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol 2010;28:2538-43
   PubMed Web of Science ®Google Scholar
• Song SN, Tomosugi N, Kawabata H, Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 2010;116:3627-34
   PubMed Web of Science ®Google Scholar
• Rusch V, Klimstra D, Venkatraman E, Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997;3:515-22
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-55
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Bunn PA Jr, Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-42
   PubMed Web of Science ®Google Scholar
• Tsao MS, Sakurada A, Cutz JC, Erlotinib in lung cancer – molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44
   PubMed Web of Science ®Google Scholar
• Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-9
   PubMed Web of Science ®Google Scholar
• Yao Z, Fenoglio S, Gao DC, TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA 2010;107:15535-40
   PubMed Web of Science ®Google Scholar
• Song L, Turkson J, Karras JG, Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003;22:4150-65
   PubMed Web of Science ®Google Scholar
• Clarke SJ, Smith JT, Gebbie C, A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer. J Clin Oncol 2009;27(15s):abstract 3025
   Google Scholar
• Rigas JR, Schuster M, Orlov SV, Effect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): results of a phase II randomized, double-blind safety and efficacy trial. J Clin Oncol 2010;28(15s):abstract 7622
   Google Scholar
• Schuster M, Rigas JR, Orlov SV, ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): results of a phase II, randomized, double-blind, placebo-controlled trial. J Clin Oncol 2010;28(15s):abstract 7631
   Google Scholar
• Catlett-Falcone R, Landowski TH, Oshiro MM, Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-15
   PubMed Web of Science ®Google Scholar
• Haga S, Terui K, Zhang HQ, Stat3 protects against fas-induced liver injury by redox-dependent and -independent mechanisms. J Clin Invest 2003;112:989-98
   PubMed Web of Science ®Google Scholar
• Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25:587-95
   PubMed Web of Science ®Google Scholar